Travere Total Stockholder Equity from 2010 to 2024

TVTX Stock  USD 7.42  0.40  5.70%   
Travere Therapeutics Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity will likely drop to about 168 M in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2010-09-30
Previous Quarter
200.8 M
Current Value
74.1 M
Quarterly Volatility
138.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere main balance sheet or income statement drivers, such as Interest Expense of 16.4 M, Selling General Administrative of 278.8 M or Other Operating Expenses of 548.1 M, as well as many exotic indicators such as Price To Sales Ratio of 6.88, Dividend Yield of 0.0 or PTB Ratio of 3.16. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
  
This module can also supplement Travere Therapeutics' financial leverage analysis and stock options assessment as well as various Travere Therapeutics Technical models . Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.

Latest Travere Therapeutics' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Travere Therapeutics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Travere Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Travere Total Stockholder Equity Regression Statistics

Arithmetic Mean153,752,046
Geometric Mean19,682,234
Coefficient Of Variation91.03
Mean Deviation125,159,305
Median200,810,000
Standard Deviation139,962,335
Sample Variance19589.5T
Range355.5M
R-Value0.51
Mean Square Error15551.4T
R-Squared0.26
Significance0.05
Slope16,045,020
Total Sum of Squares274252.4T

Travere Total Stockholder Equity History

2024168 M
2023200.8 M
202242.9 M
2021302.1 M
2020211.2 M
2019221.2 M
2018318.3 M

About Travere Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Travere Therapeutics income statement, its balance sheet, and the statement of cash flows. Travere Therapeutics investors use historical funamental indicators, such as Travere Therapeutics's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Travere Therapeutics investors may use each financial statement separately, they are all related. The changes in Travere Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Travere Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Travere Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity200.8 M168 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Travere Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Travere Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Travere Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Travere Therapeutics Stock:
Check out the analysis of Travere Therapeutics Correlation against competitors.
For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Travere Stock analysis

When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Stocks Directory
Find actively traded stocks across global markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Share Portfolio
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Is Travere Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Travere Therapeutics. If investors know Travere will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Travere Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.41)
Revenue Per Share
2.035
Quarterly Revenue Growth
0.339
Return On Assets
(0.36)
Return On Equity
(3.16)
The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Travere Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Travere Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.